Niraj Shah, MD
Family Medicine · Belleville, ILNPI 1134440969
Payments from drug & device makers
Across 348 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$664
- Pfizer$580
- AstraZeneca$573
- Lilly USA, LLC$276
- Teva Pharmaceuticals USA, Inc.$201
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,378100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $1,785 |
| Novo Nordisk | 33 | $664 |
| Pfizer | 59 | $580 |
| AstraZeneca | 29 | $573 |
| Lilly USA, LLC | 15 | $276 |
| Teva Pharmaceuticals USA, Inc. | 20 | $201 |
| Amgen | 9 | $168 |
| Sumitomo Pharma America, Inc. | 7 | $162 |
| Bayer | 8 | $129 |
| Astellas Pharma US Inc | 7 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| Boehringer Ingelheim | 5 | $71 |
| Ironwood Pharmaceuticals, Inc | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Sanofi Pasteur Inc. | 3 | $48 |
| Tris Pharma Inc | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $41 |
| Merck | 3 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $31 |
| Novartis | 2 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| GSK | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,384 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 302 | $410,051 |
| JardianceEmpagliflozin | 206 | $253,725 |
| MounjaroTirzepatide | 160 | $220,511 |
| EliquisApixaban | 199 | $202,216 |
| TrulicityDulaglutide | 65 | $101,157 |
| LinzessLinaclotide | 135 | $100,119 |
| JanuviaSitagliptin Phosphate | 59 | $78,900 |
| FarxigaDapagliflozin Propanediol | 81 | $75,469 |
| XareltoRivaroxaban | 71 | $73,560 |
| RybelsusSemaglutide | 41 | $68,974 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $41,982 |
| TradjentaLinagliptin | 31 | $37,929 |
| EntrestoSacubitril/Valsartan | 25 | $27,791 |
| ProliaDenosumab | 15 | $25,963 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $22,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $664 | $479,026343 claims |
| Lilly USA, LLCMounjaro, Trulicity | $276 | $321,668225 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $71 | $297,483249 claims |
| PfizerEliquis | $580 | $202,216199 claims |
| AbbVieLinzess, Vraylar | $1,785 | $121,571147 claims |
| MerckJanuvia, Belsomra, Dulera | $38 | $98,38297 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $573 | $97,026130 claims |
| Johnson & JohnsonXarelto | $36 | $73,56071 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $15 | $71,23997 claims |
| NovartisEntresto | $23 | $27,79125 claims |
| AmgenProlia | $168 | $25,96315 claims |
| Astellas Pharma US IncMyrbetriq | $118 | $20,49736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Belleville
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.